The Neuroscience of Bipolar Disorder: Brain Circuits, Neurochemistry, and What Science Reveals

Bipolar disorder is a complex psychiatric condition characterized by recurrent episodes of mania (or hypomania) and depression, affecting approximately 2.8% of the U.S. adult population according to the National Institute of Mental Health (NIMH). The DSM-5-TR classifies bipolar and related disorders into several subtypes — Bipolar I Disorder, Bipolar II Disorder, and Cyclothymic Disorder — each defined by the severity, duration, and pattern of mood episodes.

While bipolar disorder has been recognized clinically for well over a century, our understanding of its neurobiological underpinnings has advanced dramatically in recent decades. Modern neuroimaging, molecular genetics, and computational neuroscience have revealed that bipolar disorder is not simply a matter of "chemical imbalance" — a phrase that, while culturally persistent, vastly oversimplifies the reality. Instead, the condition involves disruptions across multiple interacting brain systems, including neural circuits that regulate emotion, reward processing, executive function, and circadian rhythms.

This article examines the current state of the neuroscience of bipolar disorder: the brain regions and circuits implicated, the neurochemical systems involved, genetic and environmental contributors, and what these findings mean for clinical practice and future treatment development.

Structural and functional neuroimaging studies have consistently identified several brain regions that show abnormalities in individuals with bipolar disorder. These regions do not operate in isolation — they form interconnected circuits that, when disrupted, produce the characteristic mood instability of the condition.

• Prefrontal Cortex (PFC): The prefrontal cortex, particularly the ventrolateral and dorsolateral regions, plays a central role in executive function, decision-making, and the top-down regulation of emotion. Neuroimaging studies consistently show reduced gray matter volume and diminished activation of the prefrontal cortex during mood episodes in individuals with bipolar disorder. This reduced prefrontal "braking" capacity is thought to contribute to impulsivity during mania and to difficulties with cognitive control across mood states.
• Amygdala: The amygdala is a key structure for processing emotional stimuli, particularly threat and reward-related information. In bipolar disorder, the amygdala tends to show heightened reactivity — meaning it responds more intensely to emotional stimuli than in healthy controls. This hyperactivation is observed during both manic and depressive episodes, and emerging evidence suggests it may persist even during euthymic (stable mood) periods, pointing to a trait-level rather than purely state-dependent abnormality.
• Anterior Cingulate Cortex (ACC): The ACC serves as a critical interface between emotional processing and cognitive control. Structural studies have identified volume reductions in the subgenual anterior cingulate cortex (sgACC) in bipolar disorder, and functional studies show aberrant activation patterns during tasks requiring emotional regulation. The sgACC is also a region heavily implicated in the mechanism of action of lithium and other mood stabilizers.
• Hippocampus: Involved in memory consolidation and contextual processing, the hippocampus shows volume reductions in some individuals with bipolar disorder, particularly those with a longer duration of illness or more frequent episodes. This suggests a potential neurotoxic effect of untreated or recurrent mood episodes on hippocampal integrity.
• Striatum and Ventral Tegmental Area (VTA): These structures are central to the brain's reward circuitry. Dysregulation in the striatal-VTA dopaminergic pathway is strongly implicated in the elevated reward sensitivity, goal-directed hyperactivity, and euphoria characteristic of manic episodes.

Rather than viewing bipolar disorder as the dysfunction of any single brain structure, contemporary neuroscience conceptualizes it as a circuit-level disorder — a disruption in the coordinated communication between brain regions. The dominant framework is the corticolimbic model, which describes a failure of top-down prefrontal control over bottom-up limbic (emotional) drive.

In a healthy brain, the prefrontal cortex modulates the intensity of emotional signals generated by the amygdala, striatum, and other limbic structures. In bipolar disorder, this regulatory relationship is weakened. During mania, reduced prefrontal inhibition allows limbic structures to drive behavior unchecked, resulting in elevated mood, impulsivity, grandiosity, and excessive goal pursuit. During depressive episodes, different patterns emerge — the prefrontal cortex may show altered connectivity with the default mode network (a set of brain regions active during self-referential thought), potentially contributing to rumination and negative self-evaluation.

Functional connectivity studies using resting-state fMRI have demonstrated that individuals with bipolar disorder show altered connectivity patterns in several large-scale brain networks, including:

• The frontolimbic circuit: Weakened connectivity between the PFC and amygdala, corresponding to impaired emotion regulation.
• The default mode network (DMN): Abnormal activity patterns associated with rumination, self-referential processing, and mood state transitions.
• The salience network: Centered on the anterior insula and dorsal ACC, this network helps determine which stimuli are behaviorally relevant. Altered salience network function may contribute to the distorted priority-setting seen in mania (e.g., pursuing risky ventures perceived as enormously important).

White matter tract integrity, assessed through diffusion tensor imaging (DTI), also appears compromised in bipolar disorder, particularly in tracts connecting frontal and temporal regions. This suggests that the communication infrastructure between critical brain areas is structurally degraded, not just functionally impaired.

Multiple neurotransmitter systems are implicated in bipolar disorder, and their interactions — rather than any single system in isolation — likely drive the condition's complex mood cycling.

Dopamine: The dopamine hypothesis remains one of the most robust neurochemical models of bipolar disorder. Elevated dopaminergic transmission in the mesolimbic pathway is associated with manic symptoms, including euphoria, increased energy, reduced need for sleep, and heightened reward-seeking. On the other hand, reduced dopamine signaling in the mesocortical pathway is thought to contribute to the anhedonia (loss of pleasure), psychomotor retardation, and amotivation seen during depressive episodes. Notably, substances that increase dopamine activity (such as stimulants or L-DOPA) can trigger manic episodes in susceptible individuals, providing pharmacological support for this model.

Serotonin: Serotonin dysregulation has long been implicated in mood disorders broadly. In bipolar disorder, evidence suggests reduced serotonergic transmission during depressive episodes. However, the role of serotonin in mania is less clear, and the relationship between serotonin and bipolar cycling is an area of active investigation. The clinical observation that serotonergic antidepressants (SSRIs) can precipitate manic switching in some individuals underscores the complexity of this system's involvement.

Glutamate and GABA: Glutamate is the brain's primary excitatory neurotransmitter, while gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter. Magnetic resonance spectroscopy (MRS) studies have detected elevated glutamate levels in certain brain regions during mania, suggesting a state of neural hyperexcitability. GABA levels, On the other hand, appear reduced — consistent with the hypothesis that an excitatory-inhibitory imbalance contributes to mood instability. Several effective mood stabilizers, including valproate and lamotrigine, modulate glutamatergic and GABAergic signaling, lending clinical support to this model.

Norepinephrine: Norepinephrine, which regulates arousal, alertness, and the stress response, shows elevated activity during manic states and reduced activity during depression. This aligns with the observable changes in energy, sleep, and psychomotor activity across mood states.

It is essential to emphasize that the "chemical imbalance" metaphor — while not entirely wrong — is a drastic simplification. Bipolar disorder involves dynamic, state-dependent shifts across multiple neurochemical systems interacting with structural and functional circuit-level abnormalities. No single neurotransmitter is "the cause" of the condition.

Genetic Architecture: Bipolar disorder is among the most heritable psychiatric conditions, with heritability estimates ranging from 60% to 85% based on twin studies. However, it follows a polygenic inheritance pattern — meaning it results from the cumulative effect of many genetic variants, each contributing a small amount of risk, rather than a single "bipolar gene."

Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with bipolar disorder risk. Key genes implicated include CACNA1C (encoding a voltage-gated calcium channel subunit critical for neuronal excitability), ANK3 (involved in the organization of ion channels at the axon initial segment), and ODZ4/TENM4 (linked to neuronal connectivity). Many of these genes overlap with those associated with schizophrenia, reinforcing the concept of a shared genetic architecture across psychotic spectrum conditions.

Epigenetics: Beyond the DNA sequence itself, epigenetic mechanisms — including DNA methylation, histone modification, and non-coding RNA regulation — influence how genes are expressed in the brain. Research suggests that environmental stressors, particularly early-life adversity, can induce lasting epigenetic changes that alter stress response systems (such as the hypothalamic-pituitary-adrenal axis), potentially increasing vulnerability to bipolar disorder in genetically predisposed individuals.

Neuroinflammation: An expanding body of evidence implicates neuroinflammatory processes in bipolar disorder. Elevated levels of pro-inflammatory cytokines — including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) — have been detected during both manic and depressive episodes. Post-mortem studies have revealed activated microglia (the brain's resident immune cells) in individuals with bipolar disorder. Whether neuroinflammation is a cause, consequence, or mediating factor in the illness progression remains an important area of ongoing investigation. Notably, lithium — the oldest and arguably most effective mood stabilizer — has demonstrated anti-inflammatory and neuroprotective properties, including promoting the expression of brain-derived neurotrophic factor (BDNF).

One of the most consistently observed features of bipolar disorder is disruption of circadian rhythms — the body's internal 24-hour clock that governs sleep-wake cycles, hormone secretion, body temperature, and metabolic function. This is not merely a symptom of mood episodes; evidence increasingly suggests that circadian dysfunction is a core pathophysiological mechanism of the disorder.

The suprachiasmatic nucleus (SCN) of the hypothalamus serves as the brain's master clock, and clock genes such as CLOCK, BMAL1, PER2, and CRY1 regulate circadian oscillations at the cellular level. Several of these genes have been implicated in bipolar disorder through genetic association studies. Disruption in the timing or amplitude of circadian rhythms can destabilize mood-regulating neural circuits and alter the balance of neurotransmitter systems.

Clinically, this manifests in ways highly familiar to individuals with bipolar disorder:

• Dramatically reduced need for sleep during mania, without subjective fatigue
• Hypersomnia or severe insomnia during depression
• Sleep disturbance as one of the most reliable prodromal signs of an approaching mood episode
• Vulnerability to mood destabilization following jet lag, shift work, or any disruption to sleep-wake routines

Interpersonal and social rhythm therapy (IPSRT), an evidence-based psychotherapy for bipolar disorder, specifically targets the stabilization of daily routines and sleep-wake cycles. The efficacy of this approach provides clinical validation for the circadian hypothesis. Additionally, research into melatonin signaling and the therapeutic potential of chronobiological interventions (such as controlled light exposure) represents a growing area of translational neuroscience in bipolar disorder.

The neuroscience of bipolar disorder has direct and increasingly practical implications for clinical care, even though we have not yet achieved the goal of biologically-based diagnosis or fully personalized treatment.

Mechanism-Informed Pharmacology: Understanding the neural systems involved helps explain why certain medications are effective. Lithium's neuroprotective effects — including promotion of BDNF expression, inhibition of glycogen synthase kinase-3 (GSK-3), and modulation of glutamatergic signaling — align directly with the neurobiological abnormalities described above. Anticonvulsant mood stabilizers like valproate and lamotrigine act on voltage-gated ion channels and the excitatory-inhibitory balance. Atypical antipsychotics modulate dopaminergic and serotonergic transmission in circuits implicated in both mania and psychosis.

Neuroprogression and Early Intervention: The concept of neuroprogression — the idea that repeated, untreated mood episodes may cause cumulative neurobiological damage — has gained substantial empirical support. Studies show progressive gray matter loss, white matter degradation, and cognitive decline associated with a greater number of mood episodes and longer duration of untreated illness. This evidence provides a strong neuroscience-based argument for early diagnosis and consistent treatment to preserve brain health over time.

Biomarker Research: While no diagnostic biomarker for bipolar disorder currently exists, research is actively pursuing candidates. These include neuroimaging patterns (such as amygdala reactivity signatures), peripheral inflammatory markers, circadian rhythm metrics from actigraphy, and polygenic risk scores derived from GWAS data. The goal is not to replace clinical evaluation but to augment it — potentially improving diagnostic accuracy, predicting treatment response, and identifying high-risk individuals before full clinical onset.

Neurostimulation Approaches: Neuroscience findings have informed the development and refinement of neurostimulation therapies. Transcranial magnetic stimulation (TMS) targeting the dorsolateral prefrontal cortex is being explored for bipolar depression, and deep brain stimulation (DBS) of the subgenual cingulate is under investigation for treatment-resistant cases. These approaches directly target the circuits identified in neuroimaging research.

As neuroscience findings enter public discourse, several misconceptions have taken hold. Clarifying these is essential for accurate understanding.

• "Bipolar disorder is just a chemical imbalance." This is an oversimplification. While neurotransmitter dysregulation is part of the picture, bipolar disorder involves structural brain changes, circuit-level dysfunction, genetic vulnerabilities, epigenetic modifications, circadian disruption, and neuroinflammatory processes. Reducing it to a single mechanism misrepresents the science.
• "A brain scan can diagnose bipolar disorder." Currently, no neuroimaging technique can diagnose bipolar disorder in an individual patient. Group-level differences are robust and scientifically informative, but they are not yet reliable enough for individual-level diagnostic use. Diagnosis remains clinical, based on symptoms, history, and course of illness as outlined in the DSM-5-TR.
• "Bipolar disorder is purely genetic — environment doesn't matter." While heritability is high, genetic risk is probabilistic, not deterministic. Environmental factors — including childhood adversity, substance use, chronic stress, and sleep disruption — interact with genetic vulnerability through epigenetic and neurobiological pathways to influence whether and how the disorder manifests.
• "Bipolar disorder affects only mood." Neuroscience research has clearly demonstrated that bipolar disorder involves significant cognitive changes, including deficits in attention, working memory, and executive function that can persist even during euthymic periods. These cognitive effects correlate with the structural and functional brain changes described throughout this article.
• "Medication just masks the symptoms without affecting the brain." Evidence suggests that effective treatments — particularly lithium — have genuine neuroprotective effects. Long-term lithium use has been associated with greater gray matter volume and reduced risk of dementia, suggesting it modifies the underlying neurobiology rather than merely suppressing symptoms.

The neuroscience of bipolar disorder has progressed substantially, but significant challenges and open questions remain.

What we know with confidence:

• Bipolar disorder involves dysfunction in corticolimbic circuits connecting the prefrontal cortex, amygdala, and striatum.
• Multiple neurotransmitter systems — dopamine, serotonin, glutamate, GABA, and norepinephrine — are differentially altered across mood states.
• The disorder has high heritability with a polygenic architecture sharing genetic overlap with schizophrenia and major depression.
• Circadian rhythm disruption is a core feature with direct relevance to clinical management.
• Neuroinflammation and neuroprogressive processes occur in at least a subset of individuals.

What remains uncertain or under active investigation:

• The precise mechanisms that trigger transitions between mood states (the "switching" problem) remain poorly understood.
• Why some individuals with genetic risk develop bipolar disorder while others do not is not fully explained by current models.
• Whether distinct neurobiological subtypes exist within the bipolar spectrum — and whether treatment should be stratified accordingly — is an emerging but unresolved question.
• The causal versus correlational nature of many observed brain changes requires further longitudinal research.

Cutting-edge research directions include the application of machine learning and artificial intelligence to multimodal neuroimaging data for pattern classification, the development of induced pluripotent stem cell (iPSC) models to study patient-derived neurons in vitro, optogenetic and chemogenetic studies in animal models to dissect specific circuit contributions, and large-scale longitudinal cohort studies tracking brain changes from the prodromal period through illness progression.

The field is moving toward a more integrated, multi-scale understanding of bipolar disorder — one that bridges genes, cells, circuits, systems, and behavior within a unified framework.

Understanding the neuroscience of bipolar disorder can be empowering, but it is not a substitute for professional clinical evaluation. If you or someone you know is experiencing patterns consistent with bipolar disorder — including distinct periods of elevated mood, reduced need for sleep, increased energy and impulsivity alternating with episodes of depression — it is important to seek evaluation from a qualified mental health professional such as a psychiatrist or clinical psychologist.

Early identification and evidence-based treatment are associated with better long-term outcomes, including reduced episode frequency, preserved cognitive function, and improved quality of life. If you are in crisis, experiencing suicidal ideation, or engaging in dangerous behavior during a mood episode, contact emergency services, the 988 Suicide and Crisis Lifeline (call or text 988), or go to your nearest emergency department.

A thorough clinical evaluation — including psychiatric history, family history, assessment of mood patterns over time, and ruling out other medical or psychiatric conditions — remains the standard of care for diagnosis. Neuroscience research enriches our understanding of the condition but does not replace this individualized clinical process.